Attenuated bovine coronavirus and related vaccines
AssigneeIntervet Inc.
InventorsCatherine M. Peters, Mark W. Mellencamp, Wenzhi Xue, Terri Wasmoen, Emilio Trigo
Life of this patent
Estimating the term…
Abstract
The present invention discloses novel attenuated bovine coronavirus isolates, compositions comprising these isolate, and methods of using such compositions in vaccines, including in live vaccines. The present invention further discloses the administration of such vaccines, including the intranasal administration of such vaccines, to aid in the prevention of respiratory disease caused by bovine coronavirus.
Claims20
An attenuated bovine coronavirus (BCoV) that comprises a genome that encodes a spike protein that has greater than 99% identity with the amino acid sequence of SEQ ID NO:
- 2;
- a hemagglutinin-esterase glycoprotein (HE) that has 98% or greater identity with the amino acid sequence of SEQ ID NO:
- 4;
- an integral membrane protein (M) that has 98% or greater identity with the amino acid sequence of SEQ ID NO:
- 6;
- and
- a nucleocapsid protein (N) that has 98% or greater identity with the amino acid sequence of SEQ ID NO:
- 10.
An attenuated bovine coronavirus (BCoV) comprising the immunogenic properties of the bovine coronavirus having the ATCC deposit number PTA-121515 or is the progeny of said BCoV.
An attenuated bovine coronavirus (BCoV) having the ATCC deposit number PTA-121515.
Dependencies are inferred from the claim text.